Pictet Asset Management Holding SA Has $28.91 Million Holdings in Genmab A/S Sponsored ADR $GMAB

Pictet Asset Management Holding SA lessened its holdings in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 1.9% during the 1st quarter, HoldingsChannel reports. The fund owned 1,077,471 shares of the company’s stock after selling 21,079 shares during the period. Pictet Asset Management Holding SA’s holdings in Genmab A/S were worth $28,909,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Founders Capital Management boosted its holdings in shares of Genmab A/S by 40.0% during the fourth quarter. Founders Capital Management now owns 1,400 shares of the company’s stock worth $43,000 after purchasing an additional 400 shares during the period. Parallel Advisors LLC increased its stake in Genmab A/S by 11.3% in the 3rd quarter. Parallel Advisors LLC now owns 4,139 shares of the company’s stock valued at $127,000 after buying an additional 419 shares during the period. CWM LLC increased its stake in Genmab A/S by 18.8% in the 4th quarter. CWM LLC now owns 2,739 shares of the company’s stock valued at $84,000 after buying an additional 433 shares during the period. Osaic Holdings Inc. lifted its position in Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after buying an additional 440 shares in the last quarter. Finally, Orion Porfolio Solutions LLC lifted its position in Genmab A/S by 2.3% in the 3rd quarter. Orion Porfolio Solutions LLC now owns 19,693 shares of the company’s stock worth $604,000 after buying an additional 441 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Stock Performance

Shares of GMAB opened at $27.64 on Thursday. The firm has a market cap of $17.23 billion, a price-to-earnings ratio of 20.94, a price-to-earnings-growth ratio of 1.77 and a beta of 0.84. The company’s fifty day moving average is $26.15 and its 200-day moving average is $28.69. The company has a quick ratio of 2.17, a current ratio of 2.18 and a debt-to-equity ratio of 0.87. Genmab A/S Sponsored ADR has a 12 month low of $20.23 and a 12 month high of $35.43.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. BNP Paribas Exane upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. Weiss Ratings lowered Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 8th. Wolfe Research assumed coverage on Genmab A/S in a research report on Friday, March 27th. They set an “outperform” rating and a $32.00 price objective for the company. Truist Financial initiated coverage on Genmab A/S in a research note on Wednesday, May 27th. They issued a “buy” rating and a $40.00 target price on the stock. Finally, The Goldman Sachs Group raised Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 22nd. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $37.93.

Genmab A/S Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.